Subacute sclerosing panencephalitis: evaluation with CT and MR.

J Brismar, G G Gascon, K V von Steyern and S Bohlega

*AJNR Am J Neuroradiol* 1996, 17 (4) 761-772

http://www.ajnr.org/content/17/4/761

This information is current as of July 13, 2023.
Subacute Sclerosing Panencephalitis: Evaluation with CT and MR

Jan Brismar, Generoso G. Gascon, Kristina Vult von Steyern, and Saeed Bohlega

**PURPOSE:** To evaluate the progression of CT and MR changes of the brain in subacute sclerosing panencephalitis (SSPE) as a basis for assessing the effects of different types of therapy. **METHODS:** Fifty-two patients with SSPE were examined, 44 with MR imaging and 42 with CT of the brain on one or more occasions. A total of 92 MR and 67 CT studies were performed. **RESULTS:** Correlation between the clinical status and the MR findings on admission was poor. Of 20 patients with clinically advanced disease, only 8 had marked MR abnormalities; 6 had normal or almost normal findings on MR examinations. Two of 4 patients with clinically mild disease had advanced MR changes. The progression of the MR findings appeared to follow a constant pattern. The earliest pathologic finding was focal, high-T2-intensity white matter changes; later atrophic changes followed. The atrophy lagged behind the white matter changes and was thus mild when white matter changes were moderate or severe. In the most advanced stage, when the patient was in a neurovegetative state, an almost total loss of white matter had usually taken place. At this stage, the corpus callosum was also thin. Basal ganglia changes, usually involving the putamina, were seen in one third of patients and cortical gray matter changes were seen in one fourth of patients examined with MR imaging. In 2 of 20 patients, MR changes regressed in parallel with clinical improvement following therapy, but in 5 patients clinical improvement was accompanied by progression of MR changes. **CONCLUSION:** The progress of MR abnormalities seen in patients with SSPE seems to follow a constant pattern, but the severity of MR changes does not always correlate well with the clinical findings. Caution must therefore be used when evaluating the effects of therapy.

**Index terms:** Brain, computed tomography; Brain, magnetic resonance; Encephalitis

Subacute sclerosing panencephalitis (SSPE) is an invariably fatal neurodegenerative disease, developing as a sequel to early childhood measles infection. Following the original measles infection, the virus becomes altered and remains dormant intracellularly, only to manifest as SSPE a decade or so later. The disease was originally described by Dawson in 1933 (1), and a major review article in 1964 (2) reported only 30 patients in North America. Increased awareness led to the identification of more cases, and in 1980, 575 cases were registered in the United States (3). Measles vaccination has now all but eradicated the disease in developed countries, but SSPE is still endemic in many developing countries, where measles vaccination in early infancy has not yet reached the World Health Organization’s goal of greater than 80% coverage. The disease also is of interest as a model for persistent viral infection of the brain. The histopathologic manifestations in the brain are indistinguishable from those of acquired immunodeficiency syndrome (AIDS) and from those seen in parainfectious and postinfectious encephalomyelitis (4).

The purpose of this study of 52 patients was to determine the time course for the development of neuroradiologic findings and to chart the distribution of lesions in order to establish a basis for the evaluation of possible effects of different types of therapy.
Subjects and Methods

During the last 8 years, we examined the brains of 52 patients with SSPE using magnetic resonance (MR) imaging and/or computed tomography (CT). Forty-two of the patients were male and 10 were female. The findings in 21 of these patients have been reported previously (5); the interpretation of the imaging findings in these patients has since been revised and a different scheme for clinical staging has been used. The age of the patients and the duration of their symptoms at the time of the initial CT or MR study are given in Figures 1 and 2. The age at the time of the original measles infection was known in only a few patients. All patients fulfilled generally accepted criteria for the diagnosis of SSPE (6) (ie, elevated serum and cerebrospinal fluid [CSF] antimeasles antibody titers and two of the following four criteria: typical clinical presentation, typical electroencephalographic [EEG] pattern, IgG in CSF greater than 20% of total protein, and typical findings on brain biopsy specimens). No brain biopsy was performed in this series. Information on the clinical stage of the disease (as defined in the Table) at presentation was available in 49 patients and appears in Figure 2. In the “Discussion,” the clinical stages suggested by Jabbour et al (6) will be denoted as J1 to J4; the stages identified in our series (7) are designated G1 to G4. The relationship between the 2 clinical staging schemes is presented in the Table.

For the CT studies, 10-mm-thick contiguous sections were obtained. For contrast enhancement, iopromide, 2 mL/kg of body weight, was used. The MR studies were performed on a 1.5-T scanner using T1-weighted, 600–700/20/2 (repetition time/echo time/excitations), and dual-echo T2-weighted, 1800–2000/30–40,80/1–2, axial sections with 0- to 2.5-mm section gaps (depending on head size) and sagittal T1-weighted images. Gadopentetate dimeglumine, 0.2 mL/kg of body weight, was given in one patient. The CT and MR studies were evaluated retrospectively for enlargement of the CSF spaces and for white matter changes, and graded subjectively in a nonblinded manner as absent (0), mild (+), moderate (++), or marked/severe (+++).

Two schemes for the clinical staging of subacute sclerosing panencephalitis (SSPE)

<table>
<thead>
<tr>
<th>SSPE stages according to Jabbour</th>
<th>SSPE stages according to Gascon</th>
</tr>
</thead>
<tbody>
<tr>
<td>J:I. Cerebral signs (mental, behavioral)</td>
<td>G:IA. Behavioral, cognitive, and personality changes, walking</td>
</tr>
<tr>
<td>J:II. Convulsive motor signs, myoclonus, incoordination, choreoathetosis, tremors</td>
<td>G:IB. Aperiodic, myoclonic spasms</td>
</tr>
<tr>
<td>J:III. Coma, opisthotonus, decerebrate rigidity; no responsiveness to any stimulus</td>
<td>G:IIA. Further mental deterioration, periodic generalized myoclonic spasms, possibly no walking because of drop spells</td>
</tr>
<tr>
<td>J:IV. Mutism, loss of cerebral cortex function, less frequent myoclonus, diminished hypertension</td>
<td>G:IIIB. Language difficulties, spasticity, ataxia, walking with assistance</td>
</tr>
<tr>
<td></td>
<td>G:IIIA. Speaking less, visual difficulties; sitting up independently, possible standing, but no independent ambulation; frequent myoclonic spasms, possible seizures</td>
</tr>
<tr>
<td></td>
<td>G:IVA. No speech, poor comprehension, possible blindness, confinement to bed, dysphagia, possible need of tubal feeding, possible choreoathetosis</td>
</tr>
<tr>
<td></td>
<td>G:IV. Neurovegetative stage, no spasms, very low background EEG activity</td>
</tr>
</tbody>
</table>

Note.—Gascon stage IA and IB are both included in Jabbour stage I; Gascon stage IIA, IIB, and IIIA are all included in Jabbour stage II; Gascon stage IIB approximately equals Jabbour stage III; and Gascon stage IV approximately equals Jabbour stage IV.
In total, 92 MR examinations were performed in 44 patients and 67 CT examinations were performed in 42 patients. Contrast medium was used in 41 CT examinations (27 patients) and in one MR study. In 25 patients, CT and MR studies were performed less than a week apart.

Results

The radiologic findings in our series included atrophy, white matter changes (ie, lesions of high T2 intensity and low CT attenuation), gray matter changes (high T2 and decreased T1 intensity), and basal ganglia involvement. Radiologic staging of SSPE was as follows:

- stage 0: no atrophy or white matter changes
- stage 1: (+) white matter changes or atrophy
- stage 2: (+) white matter changes and atrophy
- stage 3: (+++) white matter changes, 0 to + atrophy, or vice versa
- stage 4: (+++) white matter changes and atrophy
- stage 5: (++++) white matter changes, 0 to ++ atrophy, or vice versa
- stage 6: (++++) white matter changes and atrophy

The results from radiologic staging using CT information as compared with MR information was evaluated in 25 patients who were examined with both techniques within 1 week. As expected, a marked understaging was achieved when CT examinations were used to stage the disease, mainly because white matter changes are difficult to see on CT scans. Thus, the radiologic staging was thereafter based on MR results alone (ie, MR stage). Enhancement following administration of contrast medium was never observed.

The severity of atrophy was correlated with the severity of white matter changes—both graded as 0, +, ++, or +++—as determined from all 92 MR studies. In 49 studies the atrophy and white matter changes were graded as being of equal severity. In only 3 studies (2 patients) did the atrophy seem slightly more pronounced than the white matter changes, whereas in 30 studies the white matter changes appeared worse than the atrophy. In 9 studies with marked white matter changes no atrophy was seen.

Figure 3 plots the correlation between the initial MR stage and the duration of the symptoms. Although, as expected, there was a correlation between the duration of the disease and the MR stage, large variations did appear. Thus, one patient with only a 1-week history of symptoms already had moderate white matter changes, whereas another child with more than 4 years’ history of symptoms still had normal MR findings.

The correlation between the clinical stage and the severity of the MR changes was also quite weak (Fig 4). Thus, several patients with severe clinical findings (stages G:IIA, G:IIIB, or even G:IV) still had normal or almost normal MR findings (Fig 5). On the other hand, in two patients with mild clinical disease, the MR findings were markedly abnormal (Fig 6).
Cortical gray matter was involved in 11 of the 44 patients examined by MR imaging (Figs 7–9) (involvement was also seen in one patient studied only by CT). In 3 of the patients studied by MR imaging, the changes were minor; they were moderate in 7 and severe in 1. In 1 of these patients, the pons was also swollen and of high T2 intensity (Fig 7); in a second patient, high-T2-intensity lesions were seen in the left thalamus (Fig 8). In an additional patient with normal-appearing cortical gray matter, severe high-T2-intensity changes were present within the pons, brain stem, and cerebral peduncles. The gray matter changes were present on the initial MR study in 4 patients; in 8 patients gray matter changes developed between MR studies (Figs 7 and 9). No obvious correlation was found between presence of gray matter changes and either the duration of the disease or the severity of other MR changes, but gray matter was usually affected only in patients with clinically advanced disease. Thus, in 3 of 4 patients with gray matter changes initially and in 6 of 8 patients in whom gray matter lesions developed during follow up, the disease was classified as stage G:III or G:IV.

The basal ganglia were involved in 18 patients, including 15 of 44 patients who were examined with MR imaging (Figs 10 and 11). Although evenly distributed among the different MR stages, and not correlated with the length of the clinical history, basal ganglia changes were seen mainly in patients with clinical stage G:IIIa disease or higher. Thus, all but 3 of 11 patients
who had basal ganglia changes at the initial study were classified as having stage G:III disease or higher; all 7 patients in whom white matter changes developed during follow up had stage G:III or G:IV disease when the lesions were detected.

**Discussion**

SSPE is a dramatic disease, starting as minor disturbances in behavior in a previously entirely healthy child. Myoclonic attacks then develop and become increasingly more frequent, dementia follows, and within months or a few years the child is comatose, void of higher brain functions. Neuronal and glial viral cell inclusions, subacute inflammatory changes, subacute demyelination, and extensive gliosis are characteristic pathohistologic features (3). It is now known that the disease is linked to a measles infection in early childhood.

The average age of onset of SSPE has been
reported to vary from 9 to 13 years (3, 8); in our series it was 9 years. More than 90% of our patients were between 4 and 14 years old at the onset of symptoms, which is similar to other reports (8). Information about the date of the preceding measles infection was available for only a few of our patients. Other investigators have had such information available in 65% to 75% of cases (3, 8); in those series the average age at infection was between 2 and 3 years and the interval from the measles infection to the onset of SSPE symptoms averaged from 8 to 11 years.

It is still not known how the measles virus manages to survive clinically dormant for many years and why it becomes active again and causes SSPE. Possibly the immature immune system fails to destroy the virus completely, and the partially degraded virus remains in the central nervous system (CNS) (3, 9). Perhaps a simultaneous infection with another virus, such as Epstein-Barr virus, parainfluenza type 1 virus, or toxoplasmosis, might be involved in changing the properties of the measles virus (9) into those of a slow virus. Virus mutations may alter the surface antigen of the virus and thereby make it invisible to the immune response while it at the same time retaining the ability to reproduce and spread from cell to cell (10). Perhaps nonproductive, cell-associated forms of the measles virus occur naturally during a measles infection but are kept passive by the hosts' defense mechanisms, such as interferon. If suppression then fails, for instance from development of viral forms less sensitive to interferon or from a too low production of interferon, the virus may reproduce and spread within the CNS, causing SSPE (11). This hypothesis receives some support from the finding that intraventricular interferon seems to induce a clinical improvement, or at least it temporarily arrests the disease in more than half the cases (7, 11, 12).

The initial symptoms of SSPE are usually behavioral changes, such as irritability, impaired school performance, disobedience, inappropriate affection, and withdrawal. These symptoms may be ongoing for several years (13), and may be recognized only in retrospect. Myoclonic spasms then appear, often seen as drop attacks. These are initially sporadic but may later occur at intervals of only a few seconds, and will eventually prevent the patient from ambulating. The mental deterioration progresses, and a characteristic EEG pattern develops with generalized brief, bilaterally synchronous bursts of spike-wave and/or slow-wave complexes. Spasticity and ataxia become prominent and may later be followed by choreoathetosis. Language difficulties progress, patients speak less and have poor verbal comprehension; visual problems may proceed to cortical blindness. Seizures follow; the patient becomes bedridden, and may need tubal feeding. The spasticity progresses to opisthotonus and the patient lapses into a coma. Terminally, the muscular hypertonia decreases, myoclonus disappears, and the patient passes into a neurovegetative state and eventually dies (2, 6, 8, 14).

Several different staging schemes have been suggested (2, 6, 13, 15) with different numbers of intermediate stages between the first stage, which includes only behavioral symptoms and perhaps mild myoclonic attacks, and the final stage of neurovegetation. The clinical staging system used to classify disease in our patients (Table) (7) was slightly modified from previously published schemes (2, 6) to separate the middle stages better.

In a few patients, positron emission tomography was performed (16–19). In one patient with rapidly progressing SSPE, the glucose metabolism of the cortical gray matter was markedly reduced; in a patient with slowly developing
disease, the PET findings were normal (16). One boy with stage J:II disease showed luxury perfusion in the anterior half of the cerebrum and a decrease in cerebral blood flow and oxygen metabolism in the right frontal watershed zone, where CT scans showed a low-density lesion. In another boy with stage J:III disease, a marked decrease of oxygen metabolism and cerebral blood flow was found in all regions except the occipital lobe (18). Huber et al (17, 19) hypothesized, on the basis of their results from seven PET studies in four patients and on previously reported results (16, 18), that inflammation with hypermetabolism in the basal ganglia inhibits the connection between frontal, temporal, and parietal areas, thus causing the symptoms of stage J:II. When the basal ganglia later become defective, the inhibition decreases and cortical activity increases. When the disease eventually progresses to involve midline structures and the brain stem, hypermetabolism in these structures causes decline of cortical functions and impairment of consciousness, which progress to decerebrate rigidity and stage J:III disease.

The time course of SSPE is variable (Figs 2, 9, 12). In 1969 a review of 274 published cases (2) concluded that only 31% of patients survived for more than 1 year after onset of symptoms, and that only 7 of 274 showed a remission. In contrast, in a large series of 118 cases from the Middle East, noteworthy improvements and plateaus occurred in more than half the patients (13), and in 6 patients substantial spontaneous long-term improvement took place (8, 20); in all 6 cases, previously bedridden patients, incapable of self-care, became ambulatory and were able to tend to their basic needs.

Fig 9. An 11-year-old boy with 9-month history of SSPE, clinical stage G:IIIB.

A, T2-weighted (1800/80/2) MR image obtained at admission is normal except for mild focal high-T2 white matter changes (MR stage 1).

B, Seventeen months later, when the patient is still in stage G:IIIB, T2-weighted (2000/80/2) MR image shows progressive atrophy (MR stage 3). Interferon alfa combination therapy was started after this study.

C, Sixteen months later, there was clinical improvement to stage G:IIB. T2-weighted (2000/80/1) MR image also shows improvement, with only mild white matter changes apparent (MR stage 1).

D, Ten months later, the patient has progressed to clinical stage G:IIA. T2-weighted (2000/80/1) MR image shows an increase in subcortical white matter changes, involvement of the posterior limb of the internal capsule bilaterally, and gray matter changes in the right occipital lobe (MR stage 3).
needs. Similar cases of spontaneous long-term improvement (21–23) and of patients surviving for more than 10 years after diagnosis (like one of our patients) have been reported (20, 24–26). This variation in the natural course of the disease makes it difficult to evaluate the effects of therapy in small series (2, 27).

The uniformity of the mode of clinical progress in SSPE suggests a constant pattern of involvement of the CNS. Neuropathologic findings suggest that the disease initially affects the occipital regions of the cortex, progresses to the anterior parts of the cerebrum, and finally spreads to involve the subcortical structures, brain stem, and spinal cord (28). Involvement of cortical gray matter should then be responsible for the nonspecific symptoms of stage J:II. Others have claimed that an intact cerebral cortex is required to explain the appearance of the characteristic EEG changes in stage J:II disease (29); these EEG changes could then be trigged from affected centers in the brain stem and reach the cortex through intact pathways. This would be consistent with the normal findings of cortical biopsies seen early in the disease (28). Few patients (only one in our series) have been examined with MR imaging at this stage, and early gray matter changes have not been reported (the early gray matter involvement could of course be on a biochemical level, and not depictable with MR imaging).

In the next stage of the disease (J:II or G:IB), at the onset of myoclonic spasms, CT in 3 of 3 children showed abnormally small lateral ventricles (30). This finding was supported in a series of 15 patients (31) in which cerebral edema and diffuse low-attenuation white matter was found in 6 of 8 patients with J:II disease, but has been refuted in other reports (24, 32, 33). Thus, 7 patients examined during the first 4 months after onset of symptoms all had normal CT findings, without any sign of brain swelling (32); no evidence of brain swelling was found in any of 5 patients studied during the first year after onset of SSPE (only 1 of these patients was studied during the first 6 months) (24). In our series, none of 21 patients who were examined within 6 months of onset of symptoms (19 with MR imaging) showed signs of brain swelling.

Later subcortical white matter is involved with lesions identical to those of other slow virus infections of the brain, such as subacute AIDS encephalomyelitis. Immune complexes deposited in the walls of cerebral blood vessels are believed to cause damage to the blood brain barrier. The leakage of fluid and lymphocytes creates a perivascular edema and inflammation and is followed by demyelination (4). Radiologic evidence of barrier lesions has been documented in a few reports (24, 27, 34). One patient with rapidly progressing disease showed signs of acute white matter inflammation with multiple areas of contrast enhancement (24). Contrast enhancement has also been shown during an acute relapse of the disease (27). In two patients, contrast-enhanced CT scans showed normal findings, whereas radionucleide brain scans showed multiple lesions. The authors concluded that the latter technique was superior in detecting acute SSPE (34). No enhancement was observed in our series.

An alternative hypothesis would be that SSPE is primarily a subcortical disease. The whole clinical picture fits better with what neurologists would call a subcortical dementia (like Huntington disease, Parkinson disease, and so on) rather than a cortical dementia (like Alzheimer disease). The early MR changes primarily involve white matter and are more subcortical-occipital than frontal (Figs 7 and 9). It may be that the oligodendroglia (responsible for forming the myelin in the CNS) are first affected and then subsequently the basal ganglia and brain stem neurons. The myoclonic spasms are a brain stem myoclonus and occur early (stage...
G:IB or G:IIA); the cortical atrophy occurs late. Most early behavioral changes can be explained by subcortical white matter involvement of associated areas (apraxia, agnosia) and brain stem reticular (thalamocortical) mechanisms (attention and concentration difficulties).

As the disease progresses, there is an increasing loss of white matter, and atrophy becomes a more prominent feature (24, 35, 36) (Fig 12). CT findings are often negative until this late stage. Thus, in a series of 76 patients, only 22 had abnormal CT findings (37): CT findings were normal in 25 of 33 patients with stage J:III disease, in 26 of 40 patients with stage J:II disease, and in all 3 patients with stage J:I disease. In another series, 11 of 14 patients (1 stage J:I, 9 stage J:II, and 1 stage J:III) initially had normal CT findings (27). In the final stage of SSPE, most white matter is lost, the ventricles and extracerebral CSF spaces are severely widened, the corpus callosum is very thin, and posterior fossa structures are markedly atrophic (Fig 13).

Reported experiences with MR imaging in SSPE are limited (9, 25, 33, 38-44). MR imaging has major advantages in demonstrating white matter changes in SSPE (25, 33, 38, 39, 42). This was obvious from our comparison of the results of CT and MR examinations performed less than 1 week apart in 25 patients. In 11 of these patients, white matter changes were seen only on MR images.

On the initial MR study (Fig 3), all but 11 of our 44 patients had white matter changes. In 22
examinations with mild to moderate white matter changes, no atrophy was seen. In only 3 examinations (in 2 patients) was the atrophy more striking than the white matter disease.

In most patients the gray matter still appears normal on MR images, even in the most advanced clinical and MR stages; thus, in our series, signal intensity changes within the gray matter were seen in only 8 of 23 patients who were followed up with MR imaging to stage G:IIIB or G:IV disease. The gray matter lesions were not correlated with the severity of white matter changes or with atrophy (Figs 7 and 9). In 2 of our patients, central gray matter structures were involved; in 1 in addition to cortical gray matter (Fig 7) and in the second the cortical gray matter appeared normal but extensive changes were found in the brain stem and pons. Similar findings have previously been reported. One patient with J:II disease seen 3 months after onset of symptoms had normal CT findings while MR showed extensive increased-T2-intensity white matter lesions involving the supratentorial white matter, the cerebellum, and the pons (42). Six months later these white matter changes had markedly improved and the posterior fossa changes had normalized, but putaminal lesions had developed.

Basal ganglia lesions are not infrequent in SSPE, and were eventually seen in 18 of our 52 patients. Such lesions were already present on the initial imaging study in 11 patients. They were not related to the severity of other MR changes (39, 41) (Figs 10 and 11), but occurred predominantly in patients whose disease was of longer duration and more clinically advanced.

The correlation between the clinical stage of SSPE disease and the MR findings is often poor (33, 43). Thus, patients bedridden with severe disease may still have normal findings at MR examinations (Fig 9). Improvement of MR findings despite progress of the disease has also been reported (44, 45). In several of our patients, different treatment regimens were tried; in later years this included combined oral isoprinosine–intraventricular interferon alfa therapy (7). In 8 of 20 patients on this latter regimen an arrest of disease or even an improvement of the clinical status was seen. In 2 patients this improvement was associated with a slight but
clear temporary improvement in the MR findings (Fig 9). In 1 patient the MR findings remained unchanged, in 5 patients the clinical improvement was accompanied by a progression of MR abnormalities (Fig 11), and in another 2 patients a slight improvement of MR findings was accompanied by clinical improvement. In view of the large variability in the natural course of SSPE, the results of therapy must therefore be considered questionable. It is most likely that, in order to alter significantly the course of the disease, therapy must be initiated at an early stage. Presently, the diagnosis of SSPE is usually not made until major, permanent brain damage has taken place. An increased awareness of the possibility of SSPE as the cause of behavioral changes in a patient with normal findings on CT or MR examinations of the brain is probably one of many prerequisites for better therapeutic results. It is hoped that an increased use of measles vaccine in developing countries will eventually decrease the risk of SSPE.

References

34. Dodson WE, Prensky AL, Siegel BA. Radionuclide imaging in subacute sclerosing panencephalitis. *Neurology* 1979;29:749–752